Table 1.
Patient characteristics for CVID cohort and healthy controls.
| CVID cohort (n = 102) | Healthy controls (n = 28) | p-value | |
|---|---|---|---|
| Age in years mean ± SD [min-max] | 48 ± 15 [18–83] | 42 ± 10 [28–65] | 0.053* |
| Female (%) | 54% | 64% | 0.328† |
| BMI mean ± SD [min-max] | 25 ± 4 [17–39] | 24 ± 3 [19–34] | 0.232‡ |
| IVIG (%) | 18 (18%) | — | — |
| SCIG (%) | 71 (70%) | — | — |
| IVIG and SCIG’ (%) | 12 (12%) | — | — |
| Infections only (%) | 26 (26%) | — | — |
| Non-infectious complications (%) | 76 (75%) | — | — |
BMI: Body mass index. IVIG: Intravenous immunoglobulins. SCIG: Subcutaneous immunoglobulins.
‘One CVID patient did not receive any immunoglobulin substitution.
*Mann Whitney test, †Pearson Chi square test, ‡Student’s t-test.